Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 11, 1996, Pages 1083-1088

  Karamanolis, Demetrios G ^a   Papatheodoridis, George V ^a   Xourgias, Vassilios ^a  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

5 aminosalicylic acid; Acetyl 5 aminosalicylic acid; Mesalazine; Olsalazine; Systemic absorption; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; MESALAZINE; OLSALAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULCERATIVE COLITIS;

EID: 0029848723     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199611000-00010     Document Type: Article

References (43)

1. Peppercorn MA: Sulphasalazine: pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 1984, 101:377-386.
2. Lichtenstein GR: Medical therapies for inflammatory bowel disease. Curr Opin Gastroenterol 1993, 9:588-599.
3. Peppercorn MA, Goldman P: Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973, 64:240-245.
4. Azad Khan AH, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977, ii:829-835.
5. Van Hees PAM, Bekker JH, Van Tongeren JHM: Effects of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980, 21:632-635.
6. Klotz U, Maier K, Fischer C, Heinkel K: Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980, 303:1499-1502.
7. Lauritsen K, Hansen J, Ryde M, Rask-Madsen J: Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984, 86:1496-1500.
8. Das K, Eastwood MA, McManus JPA, Sircus W: Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973, 289:491-495.
9. Taffet SL, Das KM: Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983, 28:833-842.
10. Azad Khan AK, Howes DT, Piris J, Truelove SC: Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980, 21:232-240.
11. Goldman P: Will there be a next generation of sulfasalazine? Gastroenterology 1982, 83:1138-1141.
12. Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other products of 5-aminosalicylic acid. Clin Pharmacokinet 1985, 10:285-302.
13. Jarnerot G: New salicylates as maintenance treatment in ulcerative colitis. Gut 1994, 35:1155-1158.
14. Nielson OH, Bondensen S: Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983, 16:738-740.
15. Myers B, Evans DNW, Rhodes J, Evans BK, Hughes BR, Lee MG, et al.: Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites of the gastrointestinal tract. Gut 1987, 28:196-200.
16. Ryde M, Ahnfelt N: The pharmacokinetics of olsalazine sodium in healthy volunteers after a single IV dose and after oral doses with and without food. Eur J Clin Pharmacol 1988, 34:481-488.
17. SAS Institute Inc: SAS Stat User's Guide. Volume 2, Fourth Edition, Version 6 Edited by Cary NC. SAS Institute Inc; 1989:846.
18. Kulerich S, Ladefoged K, Rannem T, Ranlov PJ, The Danish Olsalazine Study Group: Prophylactic effects of olsalazine vs sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Gut 1992, 33:252-255.
19. Rijk MCM, Van Lier HJJ, Van Tongeren JHM: Relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol 1992, 87:438-442.
20. Nakshabendi IM, Duncan A, Russell RJ: Is asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis? Postgrad Med J 1992, 68:189-191.
21. Calder IC, Funder CC, Green CR, Harn KN, Tange JD: Nephrotic lesions from 5-aminosalicylic acid. BMJ 1972, 1:152-154.
22. Briggs D, Calder I, Woods R, Tange J: The influence of metabolic variation on analgesic nephrotoxicity: experiments with Gunn rat. Pathology 1982, 14:349-353.
23. Novis BH, Korzets Z, Chen P, Berheim J: Nephrotic syndrome after treatment with 5-aminosalicylic acid. BMJ 1988, 296:1442.
24. Von Muhlendahl KE: Nephritis durch 5-amino-salicylsaure. Dtsch Med Wochenschr 1989, 114:236.
25. Henning HV, Meinhold J, Eisenhauer T, Scheler F: Chronische interstitielle nephritis nach behandlung mit 5-amino-salicylsaure. Dtsch Med Wochenschr 1989, 114:1091.
26. Ruf-Ballauf W, Hofstadter F, Krentz F: Akute interstitielle nephritis durch 5-amino-salicylsaure. Internist 1989, 30:262-264.
27. Mehta RP: Acute interstitial nephritis. Can Med Assoc J 1990, 143:1031-1032.
28. Anonymous: Nephrotoxicity associated with mesalazine (Asacol). Current Problems 1990, 30:2.
29. Thuluvath PJ, Ninkovic M, Calam J, Anderson M: Mesalazine induced interstitial nephritis. Gut 1994, 35:1493-1496.
30. Colombel J-F, Bradant G, Gubler M-C, Locquet A, Comes M-C, Dehennault M, et al.: Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994, 344: 620-621.
31. Eknoyan G: Analgesic nephrotoxicity and renal papillary necrosis. Semin Nephrol 1984, 4:65-76.
32. Dubach UC, Rosner B, Pfister E: Epidemiologic study of abuse of analgesic containing phenacetin. Renal morbidity and mortality (1976-1979). N Engl J Med 1983, 308:357-362.
33. Clive DM, Stoff JS: Renal syndromes associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1984, 310:563-572.
34. Duggin GG: Mechanisms in the development of analgesic nephropathy. Kidney Int 1980, 18:553-561.
35. Abdullah AMA, Scott RB, Martin SR: Acute pancreatitis secondary to 5-aminosalicylic acid in a child with ulcerative colitis. J Pediatr Gastroenterol Nutr 1993, 17:441-444.
36. Abbudi ZH, Marsh JCW, Smith-Laing G, Gordon-Smith EC: Fatal aplastic anaemia after mesalazine. Lancet 1994, 343:542.
37. Honeybourne D: Mesalazine toxicity. BMJ 1994, 308:533.
38. Ireland A, Priddle JD, Jewell DP: Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci 1990, 78:105-111.
39. Van Hogezand RA, Van Hees PA, Van Gorp JP, Van Lier HJ, Bakker JH, Wesseling P, et al.: Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther 1988, 2:33-40.
40. Patrono C, Piercucci A: Renal effects of non-steroidal anti-inflammatory drugs in chronic glomerular disease. Am J Med 1986, 81(suppl. 2B):71-83.
41. Reimann IW, Golbs E, Fisher C: Influence of intravenous acetyl-salicylic acid and sodium salicylate on human renal function and lithium clearance. Eur J Clin Pharmacol 1985, 29:435-441.
42. Abraham PA, Stillman MT: Salsalate exacerbation of chronic renal insufficiency: relation to inhibition of prostaglandin synthesis. Arch Intern Med 1987, 147:1674-1676.
43. Staerk Laursen L, Stockholm M, Bukhave K, Rask-Madsen J, Lauritsen K: Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values and urinary excretion. Gut 1990, 31:1271-1276.